$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

$irwd Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000110465913061714 Filed on August 08, 2013

Income Statement

Concept	2013 Q2	2012 Q2
Revenue	$9.663M	$14.60M
YoY Change	-33.83%	29.68%
Cost Of Revenue	$3.418M	$0.00
YoY Change
Gross Profit	$6.245M	$14.60M
YoY Change	-57.23%
Gross Profit Margin	64.63%	99.97%
Selling, General & Admin	$30.87M	$20.10M
YoY Change	53.59%	86.1%
% of Gross Profit	494.32%	137.66%
Research & Development	$24.09M	$32.24M
YoY Change	-25.27%	66.18%
% of Gross Profit	385.8%	220.81%
Depreciation & Amortization	$2.800M	$2.800M
YoY Change	0.0%	-3.45%
% of Gross Profit	44.84%	19.18%
Operating Expenses	$54.96M	$52.34M
YoY Change	5.02%	73.3%
Operating Profit	-$59.88M	-$40.83M
YoY Change	46.64%
Interest Expense	$5.318M	$13.00K
YoY Change	40807.69%	-87.0%
% of Operating Profit
Other Income/Expense, Net	-$5.269M	$31.00K
YoY Change	-17096.77%	-71.3%
Pretax Income	-$65.10M	-$40.80M
YoY Change	59.56%	117.02%
Income Tax
% Of Pretax Income
Net Earnings	-$65.10M	-$40.80M
YoY Change	59.56%	117.02%
Net Earnings / Revenue	-673.7%	-279.38%
Basic Earnings Per Share	-$0.57	-$0.38
Diluted Earnings Per Share	-$0.57	-$0.38
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$300.5M	$157.7M
YoY Change	90.55%	-21.58%
Cash & Equivalents	$219.5M	$85.60M
Short-Term Investments	$81.10M	$70.60M
Other Short-Term Assets	$9.600M	$6.000M
YoY Change	60.0%	27.66%
Inventory	$20.38M
Prepaid Expenses
Receivables	$5.300M	$2.500M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$335.8M	$166.1M
YoY Change	102.16%	-20.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$35.01M	$34.90M
YoY Change	0.32%	4.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.091M	$7.700M
YoY Change	-33.88%	-2.53%
Total Long-Term Assets	$48.25M	$42.60M
YoY Change	13.27%	3.15%
TOTAL ASSETS
Total Short-Term Assets	$335.8M	$166.1M
Total Long-Term Assets	$48.25M	$42.60M
Total Assets	$384.0M	$208.7M
YoY Change	84.01%	-16.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.569M	$10.60M
YoY Change	-38.03%	63.08%
Accrued Expenses	$17.12M	$20.10M
YoY Change	-14.81%	66.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$300.0K
YoY Change	-33.33%	50.0%
Total Short-Term Liabilities	$43.97M	$49.10M
YoY Change	-10.46%	-30.65%
LONG-TERM LIABILITIES
Long-Term Debt	$174.8M	$400.0K
YoY Change	43600.0%	-20.0%
Other Long-Term Liabilities	$1.653M	$30.40M
YoY Change	-94.56%	-36.93%
Total Long-Term Liabilities	$1.653M	$30.80M
YoY Change	-94.63%	-36.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.97M	$49.10M
Total Long-Term Liabilities	$1.653M	$30.80M
Total Liabilities	$45.62M	$79.90M
YoY Change	-42.9%	-33.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$664.1M
YoY Change
Common Stock	$803.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$139.4M	$128.8M
YoY Change
Total Liabilities & Shareholders Equity	$384.0M	$208.7M
YoY Change	84.01%	-16.42%

Cashflow Statement

Concept	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$65.10M	-$40.80M
YoY Change	59.56%	117.02%
Depreciation, Depletion And Amortization	$2.800M	$2.800M
YoY Change	0.0%	-3.45%
Cash From Operating Activities	-$80.10M	-$43.10M
YoY Change	85.85%	136.81%
INVESTING ACTIVITIES
Capital Expenditures	-$2.000M	-$2.400M
YoY Change	-16.67%	20.0%
Acquisitions
YoY Change
Other Investing Activities	$55.20M	-$300.0K
YoY Change	-18500.0%	-101.44%
Cash From Investing Activities	$53.20M	-$2.800M
YoY Change	-2000.0%	-114.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	141.1M	1.300M
YoY Change	10753.85%	0.0%
NET CHANGE
Cash From Operating Activities	-80.10M	-43.10M
Cash From Investing Activities	53.20M	-2.800M
Cash From Financing Activities	141.1M	1.300M
Net Change In Cash	114.2M	-44.60M
YoY Change	-356.05%	-2447.37%
FREE CASH FLOW
Cash From Operating Activities	-$80.10M	-$43.10M
Capital Expenditures	-$2.000M	-$2.400M
Free Cash Flow	-$78.10M	-$40.70M
YoY Change	91.89%	151.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	irwd	Available For Sale Securities Debt Maturity Period Range High AvailableForSaleSecuritiesDebtMaturityPeriodRangeHigh	P1Y
CY2013Q2	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions	13	item
CY2012Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions	3	item
CY2012Q4	irwd	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions For More Than Twelve Months AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsForMoreThanTwelveMonths	0	item
CY2013Q2	irwd	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions For More Than Twelve Months AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsForMoreThanTwelveMonths	0	item
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	3000000	USD
CY2013Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	30900000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></i></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of condensed consolidated financial statements requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company’s management evaluates its estimates, including those related to revenue recognition, available-for-sale securities, inventory valuation and related reserves, impairment of long-lived assets, income taxes including the valuation allowance for deferred tax assets, research and development expense, contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> </div>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18814669	shares
CY2013Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2012Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	31523000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	6000	USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	1000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	31528000	USD
CY2013Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	81078000	USD
CY2013Q2	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	5000	USD
CY2013Q2	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	6000	USD
CY2013Q2	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	81077000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20515228	shares
CY2013Q2	us-gaap	Inventory Net InventoryNet	20379000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	6699000	USD
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11770000	USD
CY2013Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1326000	USD
CY2013Q2	us-gaap	Interest Payable Current InterestPayableCurrent	855000	USD
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3173000	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17124000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14594000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1031000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5546000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21171000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4817000	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4056000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10092000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7777000	USD
	dei	Entity Registrant Name EntityRegistrantName	IRONWOOD PHARMACEUTICALS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001446847
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	136700000	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	31528000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	457000	USD
CY2012Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1030000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8026000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	184440000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	7647000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37537000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	283000	USD
CY2012Q4	us-gaap	Assets Assets	229907000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14217000	USD
CY2012Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	7509000	USD
CY2012Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	5664000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	261000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	2735000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3381000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	54938000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	308000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	11593000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	18024000	USD
CY2013Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	174628000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	992000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	648955000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-505016000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	144052000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	229907000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	384031000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	139416000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	43966000	USD
CY2013Q2	us-gaap	Assets Assets	384031000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	335780000	USD
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q2	us-gaap	Revenues Revenues	14604000	USD
	us-gaap	Revenues Revenues	26852000	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	3418000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4649000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32238000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61748000	USD
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20099000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	36418000	USD
CY2012Q2	irwd	Collaboration Expense CollaborationExpense	3101000	USD
	irwd	Collaboration Expense CollaborationExpense	5156000	USD
CY2012Q2	us-gaap	Costs And Expenses CostsAndExpenses	55438000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	103322000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-40834000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-76470000	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	13000	USD
	us-gaap	Interest Expense InterestExpense	27000	USD
CY2012Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	44000	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	93000	USD
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	31000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	66000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-40803000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-76404000	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	107078150	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105414607	shares
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-65149000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-159051000	USD
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	69543000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-59880000	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5269000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10338000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-148713000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	161631000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-12000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-15000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-12000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40815000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76419000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-13000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65162000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-159057000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5490000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-173323000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7777000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-579000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	937000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1814000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	500000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3065000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-64000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6713000	USD
	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-103000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-24278000	USD
	irwd	Increase Decrease In Deferred Rent Payables IncreaseDecreaseInDeferredRentPayables	-1128000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	661000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-86169000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	44655000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	50225000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7037000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	137766000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1467000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	85228000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	175000000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	7717000	USD
	irwd	Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock	2343000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	134000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	87437000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-199000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	219461000	USD
CY2013Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	198000	USD
CY2013Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	81077000	USD
CY2013Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	5298000	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9565000	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	8147000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35013000	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5091000	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	6569000	USD
CY2013Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	7268000	USD
CY2013Q2	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	4946000	USD
CY2013Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	223000	USD
CY2013Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	2762000	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5074000	USD
CY2013Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	10218000	USD
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13952000	USD
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1653000	USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	803363000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-664067000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000	USD
CY2013Q2	us-gaap	Revenues Revenues	9663000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24093000	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30870000	USD
CY2013Q2	irwd	Collaboration Expense CollaborationExpense	11162000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	5318000	USD
CY2013Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	49000	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	113441391	shares
	us-gaap	Revenues Revenues	12918000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56846000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64244000	USD
	irwd	Collaboration Expense CollaborationExpense	35892000	USD
	us-gaap	Interest Expense InterestExpense	10439000	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	101000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	110771851	shares
CY2013Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-13000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-6000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5577000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10092000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-887000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	3811000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3447000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-72000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10098000	USD
	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-718000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2379000	USD
	irwd	Increase Decrease In Deferred Rent Payables IncreaseDecreaseInDeferredRentPayables	-1348000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	144584000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	94142000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4890000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55332000	USD
	irwd	Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock	6515000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	148000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	311416000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	82761000	USD

Files In Submission

Name	View Source	Status
0001104659-13-061714-index-headers.html	Edgar Link	pending
0001104659-13-061714-index.html	Edgar Link	pending
0001104659-13-061714.txt	Edgar Link	pending
0001104659-13-061714-xbrl.zip	Edgar Link	pending
a13-12580_110q.htm	Edgar Link	pending
a13-12580_1ex10d1.htm	Edgar Link	pending
a13-12580_1ex31d1.htm	Edgar Link	pending
a13-12580_1ex31d2.htm	Edgar Link	pending
a13-12580_1ex32d1.htm	Edgar Link	pending
a13-12580_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
irwd-20130630.xml	Edgar Link	completed
irwd-20130630.xsd	Edgar Link	pending
irwd-20130630_cal.xml	Edgar Link	unprocessable
irwd-20130630_def.xml	Edgar Link	unprocessable
irwd-20130630_lab.xml	Edgar Link	unprocessable
irwd-20130630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

2013 Q2 Form 10-Q Financial Statement

#000110465913061714 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD IRONWOOD PHARMACEUTICALS INC Stock $irwd

2013 Q2 Form 10-Q Financial Statement

#000110465913061714 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd